Physician profile
Ruby N Derogene
NPI 1366957441
$1,360.68
in general payments reported to CMS, 2019-2025
24 companies · $85.68 in 2025
The $85.68 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,275 · 2025: $85.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $85.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $85.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $168.90 | 2021 | |
| Abbvie INC. | $145.73 | 2021 | |
| Novo Nordisk INC | $138.64 | 2021 | |
| Lilly USA, LLC | $118.93 | 2021 | |
| Amarin Pharma, INC. | $92.76 | 2021 | |
| Glaxosmithkline, LLC. | $87.92 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.22 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $71.96 | 2021 | |
| Merck Sharp & Dohme LLC | $55.77 | 2025 | Zerbaxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.57 | 2021 | |
| Astellas Pharma US INC | $43.66 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $40.95 | 2021 | |
| Amgen INC. | $32.43 | 2021 | |
| Shionogi INC | $29.91 | 2025 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $29.65 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27.89 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $27.87 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $27.15 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.00 | 2021 | |
| Philips North America LLC | $14.40 | 2021 | |
| Abbott Laboratories | $14.34 | 2021 | |
| Orexo US, INC. | $14.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.56 | 2021 | |
| Dexcom, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Derogene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.